Caplight Directory>Companies>EpiDisease-preview>Epidisease


EpiDisease

EpiDisease

Private
PaternaHealthcare & Life Scienceshttps://epidisease.com/

Last Round

VC Round

Apr 15, 2021

Total Funding Raised

$402,480

Company Overview

EpiDisease is a biotechnology company that develops and commercializes a pipeline of patented genetic and epigenetic in vitro diagnostic (IVD) products and clinical software tools for the precision management of complex human diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine, Drug Discovery, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales, Government Contracts

AI Layer

Application

Keywords

epigeneticsin-vitro diagnosticsIVDepigenetic biomarkersDNA methylation analysisepigenetic clockaging clockepigenetic servicesgenetic testingbiological age testmolecular diagnosticscompanion diagnosticsnon-invasive diagnosticsscoliosis testmiRNA analysisAI diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EpiDisease Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

EpiDisease Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 15, 2021
GrantJul 25, 2018
View all Funding Rounds

Key People

Founding team and executive leadership

Jose Luis García-Giménez

CEO

Executive Team

EpiDisease Investors

Notable investors and investment history

InvestorRounds
Fundación BotínVC Round, Grant
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2025

    Monthly visitors increased 323% MoM to 2.3K.

  • Dec 11, 2023

    Grew 23% QoQ from 13 to 16 employees.

View all signals

EpiDisease Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EpiDisease Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EpiDisease's valuation, stock price, and market status.

Firmographic Details

HeadquartersPaterna
Employee Range11
Year Founded2014
Last FundingApr 15, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.